chiesi idebenone_thumbnail
September 23, 2025

FDA Grants Priority Review to Idebenone for Leber Hereditary Optic Neuropathy

A rare disease, a rare chance. FDA fast-tracks idebenone for LHON.  The U.S. Food and Drug Administration (FDA) doesn’t hand…

day_2_2
September 6, 2025

Ooh La La… Retina! The Best of Day 2 at EURETINA 2025

From drug delivery wins to chatbot scribes, Day 2 in Paris proves retina science is très on point.  As the…

popular posts
Article 1
September 6, 2025

Breaking the Injection Habit: Smarter Retinal Drug Delivery Unveiled at EURETINA 2025

EURETINA Thumb session 1_Euretina Session 3
September 5, 2025

The Slow Burn of Dry AMD at EURETINA 2025

latest posts
chiesi idebenone_thumbnail
September 23, 2025

FDA Grants Priority Review to Idebenone for Leber Hereditary Optic Neuropathy

day_2_2
September 6, 2025

Ooh La La… Retina! The Best of Day 2 at EURETINA 2025

Article 1
September 6, 2025

Breaking the Injection Habit: Smarter Retinal Drug Delivery Unveiled at EURETINA 2025

Outlook therapeutics_thumbnail
September 5, 2025

Outlook Therapeutics Requests Type A Meeting with FDA After Second Rejection of Wet AMD Drug Bevacizumab

EURETINA Thumb session 1_Euretina Session 3
September 5, 2025

The Slow Burn of Dry AMD at EURETINA 2025

Radiation Maculopathy Formally _thumbnail
August 28, 2025

Radiation Maculopathy Formally Recognized as Roca Therapeutics Wins First EMA Orphan Nod for RCT002

first patients treated in jCyte_Thumbnail
August 20, 2025

First Patients Dosed in jCyte’s Phase II JC02-88 Trial for Retinitis Pigmentosa

Aflib_8_mg_6_months_intervals_in_EU_ _thumbnail
June 30, 2025

Eylea 8 mg Approved in EU for 6-Month Dosing in nAMD and DME

Discover our fascinating content at issuu

explore